Allergies to sulfonamide antibiotics and sulfur-containing drugs

Annals of Allergy, Asthma and Immunology

Volumn 100, Issue 2, 2008, Pages 91-101

  Dibbern Jr , Donald A ^a   Montanaro, Anthony ^b  

^a Allergy Clinic   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; SULFONAMIDE; SULFUR DERIVATIVE;

ANAMNESIS; ANOREXIA; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DESENSITIZATION; DIAGNOSTIC ACCURACY; DIARRHEA; DRUG HYPERSENSITIVITY; ERYTHEMA; FEVER; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; INCIDENCE; KIDNEY TUBULE ACIDOSIS; LANGUAGE; MEDICAL LITERATURE; NAUSEA; PRIORITY JOURNAL; PRURITUS; PUBLICATION; REVIEW; RISK FACTOR; SIDE EFFECT; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; URTICARIA; VERTIGO; VOMITING;

EID: 39049150437     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1081-1206(10)60415-2     Document Type: Review

References (75)

1. Montanaro A. Sulfonamide allergy. Immunol Allergy Clin North Am. 1998;18:843-850.
2. Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy. 2004;24:856-870.
3. DeSwarte RD, Patterson R. Drug allergy. In: Patterson, R, Grammer, LC, Greenberger, PA, eds. Allergic Diseases: Diagnosis and Management. 5th ed. Philadelphia, PA: Lippincott; 1997:317.
4. World Health Organization. International Drug Monitoring: The Role of National Centres. Geneva, Switzerland: World Health Organization; 1972:9. Tech Rep Ser WHO No. 498.
5. Brown EG, Wood L, Wood S. The Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf. 1999;20:109-117.
6. Brown EG. Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART. Drug Saf. 2002;25:445-452.
7. Rawlins MD. Clinical pharmacology: adverse reactions to drugs. BMJ (Clin Res Ed). 1981;282:974-976.
8. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255-1259.
9. Hunziker T, Bruppacher R, Kuenzi UP, et al. Classification of ADRs: A proposal for harmonization and differentiation based on the experience of the comprehensive hospital drug monitoring Bern/St. Gallen, 1974-1993. Pharmacoepidemiol Drug Saf. 2002;11:159-163.
10. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28:851-870.
11. Borda IT, Slone D, Jick H. Assessment of adverse reactions within a drug surveillance program. JAMA. 1968;205:645-647.
12. Domagk G. Ein Beitrag zur Chemotherapie der bakteriellen Infektionen. Dt Med WSchr. 1935;61:250-253.
13. Bushby SRM, Hitchings GH. Trimethoprim, a sulphonamide potentiator. Br J Pharmacol Chemother. 1968;33:72-90.
14. Patel RB, Welling PG. Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole). Clin Pharmacokinet. 1980;5: 405-423.
15. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions: A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256: 3358-3363.
16. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis. 1982;4:426-428.
17. Kennedy CA, Pimentel JA, Lewis DE, et al. Crossover of human immunodeficiency virus-infected patients from aerosolized pentamidine to trimethoprim-sulfamethoxazole: Lack of hematologic toxicity and relationship of side effects to CD4+ lymphocyte count. J Infect Dis. 1993;168:314-317.
18. Jaffe HS, Abrams DI, Ammann AJ, et al. Complications of cotrimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet. 1983;2:1109-1111.
19. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993;328:1670-1674.
20. Solensky R. Drug desensitization. Immunol Allergy Clin North Am. 2004;24:425-443.
21. Bjorkman A, Phillips-Howard PA. Adverse reactions to sulfa drugs: implications for malaria chemotherapy. Bull World Health Organ. 1991; 69:297-304.
22. Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin North Am. 2004;24:477-490.
23. Adkinson NF. Drug allergy. In: Middleton E, Ellis EF, Yunginger JW, et al, eds. Allergy: Principles and Practice. 5th ed. St Louis, MO: Mosby; 1998:1212.
24. Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev. 1996; 15:9-50.
25. Teo L, Tan E. Sulphasalazine-induced DRESS. Singapore Med J. 2006; 47:237-239.
26. Naisbitt DJ, Farrell J, Gordon SF, et al. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Molec Pharmacol. 2002;62:628-637.
27. Roujeau, J-C, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1607.
28. Absy M, Glatt AE. Antibiotic allergy: inaccurate history taking in a teaching hospital. Southern Med J. 1994;87:805-807.
29. Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients. AIDS. 1993;7:65-71.
30. Bonfanti P, Pusterla L, Parazzini F, et al. The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study. Biomed Pharmacother. 2000;54:45-49.
31. Gruchalla RS, Sullivan TJ. Detection of human IgE to sulfamethoxazole by skin testing with sulfamethoxazoyl-poly-L-tyrosine. J Allergy Clin Immunol. 1991;88:784-792.
32. Gompels MM, Simpson N, Snow M, et al. Desensitization to cotrimoxazole (trimethoprim-sulfamethoxazole) in HIV-infected patients: is patch testing a useful predictor of reaction? J Infect. 1999;38:111-115.
33. Tornero P, deBarrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. Contact Derm. 2004;51:57-62.
34. Rieder MJ, Uetrecht J, Shear NH, et al. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med. 1989;110:286-289.
35. Neuman MG, Malkiewicz IM, Shear NH. A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clin Biochem. 2000; 33:517-524.
36. Neuman MG, Malkiewicz IM, Phillips EJ, et al. Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals. Ther Drug Monitor. 2002;24:728-736.
37. Carrington DM, Earl HS, Sullivan TJ. Studies of human IgE to a sulfonamide determinant. J Allergy Clin Immunol. 1987;79:442-447.
38. Rich JD, Sullivan T, Greineder D, Kazanjian PH. Trimethoprim/ sulfamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons. Ann Allergy Asthma Immunol. 1997;79: 409-414.
39. Empedrad R, Darter AL, Earl HS, Gruchalla RS. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol. 2003;112:629-630.
40. Gruchalla RS. Diagnosis of allergic reactions to sulfonamides. Allergy. 1999;58:28-32.
41. Stumpf JL, Shehab N, Patel AC. Safety of angiotensin-converting enzyme inhibitors in patients with insect venom allergies. Ann Pharmacother. 2006;40:699-703.
42. Bernstein DI, Wanner M, Borish L, et al. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol. 2004;113:1129-1136.
43. Caumes E, Guermonprez G, Lecompte C, et al. Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Arch Dermatol. 1997;133:465-469.
44. Leoung GS, Stanford JF, Giordano MF, et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis. 2001;184:992-997.
45. Moreno JN, Poblete RB, Maggio C, et al. Rapid oral desensitization for sulfonamides in patients with the acquired immunodeficiency syndrome. Ann Allergy Asthma Immunol. 1995;74:140-146.
46. deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA. 1987;278:1895-1906.
47. Smith JW, Seidl LG, Cluff LE. Studies on the epidemiology of adverse drug reactions: V. Clinical factors influencing susceptibility. Ann Intern Med. 1966;65:629-640.
48. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349:1628-1635.
49. Hemstreet BA, Page RL. Sulfonamide allergies and outcomes related to use of potentially cross-reactive drugs in hospitalized patients. Pharmacotherapy. 2006;26:551-557.
50. Korraa H, Saadeh C. Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole. South Med J. 1996;89:272-277.
51. Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology. 1987;93: 1255-1262.
52. Taffet SL, Das KM. Desensitization of patients with inflammatory bowel disease to sulfasalazine. Am J Med. 1982;73:520-524.
53. Purdy BH, Philips DM, Summers RW. Desensitization for sulfasalazine skin rash. Ann Intern Med. 1984;100:512-514.
54. Kummerle-Deschner J, Dannecker G. Sulphasalazine desensitization in a paediatric patient with juvenile chronic arthritis. Acta Paediatr. 1995; 84:952-954.
55. Wall GC. Ethacrynic acid and the sulfa-sensitive patient. Arch Intern Med. 2003;163:116-117.
56. Earl G, Davenport J, Narula J. Furosemide challenge in patients with heart failure and adverse reactions to sulfa-containing diuretics. Ann Intern Med. 2003;138:358-359.
57. Lee AG, Anderson R, Kardon RH, Wall M. Presumed "sulfa allergy" in patients with intracranial hypertension treated with acetazolamide or furosemide: cross-reactivity, myth, or reality? Am J Ophthalmol. 2004; 138:114-118.
58. Juang P, Page RL II, Zolty R. A successful rapid desensitization protocol in a loop diuretic allergic patient. J Cardiac Fail. 2005;11:481.
59. Chichmanian RM, Papasseudi G, Hieronimus S, et al. Allergies aux sulfonylurees hypoglycemiantes: les reactions croisees existent-elles? [Hypersensitivity to hypoglycemic sulfonylurea compounds: are there cross-reactions?] Therapie. 1991;46:163-167.
60. Alvarez-Thull L, Rosenwasser LJ, Brodie TD. Systemic allergy to endogenous insulin during therapy with recombinant DNA (rDNA) insulin. Ann Allergy Asthma Immunol. 1996;76:253-256.
61. Panczel P, Hosszufalusi N, Horvath MM, Horvath A. Advantage of insulin lispro in suspected insulin allergy. Allergy. 2000;55:409-410.
62. Nagai T, Nagai Y, Tomizawa T, Mori M. Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin infusion. Intern Med. 1997;36:575-578.
63. deShazo RD, Galloway JA. Insulin allergy. Ann Allergy Asthma Immunol. 1996;76:217-218.
64. Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: Fact or fiction? Ann Pharmacother. 2005;39:290-301.
65. Shapiro LE, Knowles SR, Weber E, et al. Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. Drug Saf. 2003;26: 187-195.
66. Patterson R, Bello AE, Lefkowith J. Immunologic tolerability profile of celecoxib. Clin Ther. 1999;21:2065-2079.
67. La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005;28:917-924.
68. Agrawal S, Agarwalla A. Dapsone hypersensitivity syndrome: a clinico-epidemiologic review. J Dermatol. 2005;32:883-889.
69. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med. 1990;323:776-782.
70. Beumont MG, Graziani A, Ubel PA, MacGregor RR. Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. Am J Med. 1996;100:611-616.
71. Jorde UP, Horowitz HW, Wormser GP. Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole- intolerant, HIV-infected individuals. AIDS. 1993;7:355-359.
72. Holtzer CD, Flaherty JF Jr, Coleman RL. Cross-reactivity in HIV-infected patients switched from trimethoprim-sulfamethoxazole to dapsone. Pharmacotherapy. 1998;18:831-835.
73. Blum RN, Miller LA, Gaggini LC, Cohn DL. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr. 1992;5:341-347.
74. Metroka CE, Lewis NJ, Jacobus DP. Desensitization to dapsone in HIV-positive patients. JAMA. 1992;267:512.
75. Cook DE, Kossey JL. Successful desensitization to dapsone for Pneumocystis carinii prophylaxis in an HIV-positive patient. Ann Pharmacother. 1998;32:1302-1305.